3-methylbut-2-enyl 4-hydroxybenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methylbut-2-enyl 4-hydroxybenzoate
• 英文别名: Prenyl 4-hydroxybenzoate
• 化学式: C₁₂H₁₄O₃
• mdl: MFCD24388420
• 分子量: 206.241
• InChiKey: IABAZSGILBXUEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methylbut-2-enyl 4-hydroxybenzoate 在 乌洛托品 作用下， 反应 1.0h， 以50%的产率得到4-hydroxy-3-(3'-hydroxy-3'-methylbutyl)benzoic acid
  参考文献：
  名称：

  Dey, Sankar P.; Dey, Dilip K., Journal of the Indian Chemical Society, 2009, vol. 86, # 5, p. 485 - 487

  摘要：

  DOI：
• 作为产物：
  描述：

  3-Methylbut-2-enyl 4-(3-methylbut-2-enoxy)benzoate 在 sodium tetrahydroborate 、 氯化锆(IV) 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以75%的产率得到3-methylbut-2-enyl 4-hydroxybenzoate
  参考文献：
  名称：

  Highly efficient and chemoselective cleavage of prenyl ethers using ZrCl4/NaBH4

  摘要：

  An efficient and chemoselective deprotection of prenyl ethers of phenols and alcohols with ZrCl4/NaBH4 in DCM was achieved in high yields. The selectivity of prenyl ether deprotection is well demonstrated by carrying out the reaction in the presence of several other ether and ester functionalities. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(03)00330-7

文献信息

• Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
  申请人：Mazzio Anne Elizabeth

  公开号：US20060035981A1

  公开（公告）日：2006-02-16

  This invention discloses a method and formulation for treatment/prevention of human and animal cancers. The invention is designed to exploit the vulnerability of cancer with regards to its anaerobic requirement for non-oxidative phosphorylation of glucose to derive energy, which is opposite to the host. The composition is comprised of a combination of one or more of (A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone, ubiquinones (5-45) (B) compound(s) capable of augmenting oxidative phosphorylation such as a riboflavin containing compound and/or ubiquinone (50) (C) 2′,3,4′5,7-pentahydroxyflavone or a lactic acid dehydrogenase inhibitor and (D) compounds (s) that antagonize gluconeogenesis from non-glucose carbon based substrates. The combination of these substances should favor oxidative loss of carbon through decarboxylation reactions, suppress gluconeogenesis and initiate collapse of glycolysis in tumor tissue, a chemical manipulation that should be non-toxic or perhaps even beneficial to normal respiring host tissue. Pilot studies indicate the treatment to be effective without side effects.

  本发明公开了一种治疗/预防人类和动物癌症的方法和制剂。本发明旨在利用癌症对葡萄糖的非氧化磷酸化以获取能量的厌氧需求这一弱点，这一点与宿主相反。本发明的组合物由以下一种或多种成分组合而成 (A) 2,3-二甲氧基-5-甲基-1,4-苯醌、泛醌（5-45） (B) 能够增强氧化磷酸化的化合物，如含核黄素的化合物和/或泛醌（50） (C) 2′、3,4′5,7-五羟基黄酮或乳酸脱氢酶抑制剂；(D) 能拮抗非葡萄糖碳基底物葡萄糖生成的化合物。这些物质的组合应有利于通过脱羧反应氧化失碳，抑制葡萄糖生成，并启动肿瘤组织中糖酵解的崩溃，这种化学操作对正常呼吸的宿主组织应该是无毒的，甚至可能是有益的。试验研究表明，这种治疗方法有效且无副作用。
• Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
  申请人：Slesarev Alexei

  公开号：US20060068386A1

  公开（公告）日：2006-03-30

  We have determined the complete 1,694,969 nucleotide sequence of the GC-rich genome of Methanopyrus kandleri using a novel approach. It is based on unlinking genomic DNA with the ThermoFidelase version of M. kandleri topoisomerase V and cycle sequencing directed by 2′-modified oligonucleotides (Fimers). 3.3× sequencing redundancy was sufficient to assemble the genome with <1 error per 40 kb. Using a combination of sequence database searches and coding potential prediction, 1692 protein-coding genes and 39 genes for structural RNAs were identified. M. kandleri proteins show an unusually high content of negatively charged amino acids, which might be an adaptation to its high intracellular salinity. Previous phylogenetic analysis of 16S RNA suggested that M. kandleri belonged to a very deep branch, close to the root of the archaeal tree. However, genome comparisons, using both trees constructed from concatenated alignments of ribosomal proteins and trees based on gene content, indicate that M. kandleri consistently groups with other archaeal methanogens. M. kandleri shares the set of genes implicated in methanogenesis and, in part, its operon organization with Methanococcus jannaschii and Methanothermobacter thermoautotrophicus . These findings indicate that archaeal methanogens are monophyletic. A distinctive feature of M. kandleri is the paucity of proteins involved in signaling and regulation of gene expression: Also, M. kandleri appears to have fewer genes acquired via lateral transfer than other archaea. These features might reflect the extreme habitat of this organism.

  我们测定了富含 GC 的甲壳虫基因组 1 694 969 个核苷酸的完整序列。 Methanopyrus kandleri 采用了一种新方法。该方法基于用 ThermoFidelase 版本的 的 ThermoFidelase 版本解开基因组 DNA 拓扑异构酶 V 和 2′修饰寡核苷酸（Fimers）引导的循环测序。3.3 倍的测序冗余足以组装基因组，每 40 kb 的误差小于 1。通过序列数据库搜索和编码潜能预测相结合的方法，确定了 1692 个蛋白质编码基因和 39 个结构 RNA 基因。 M. kandleri 蛋白质显示出异常高的带负电荷氨基酸含量，这可能是为了适应其细胞内的高盐度。先前的 16S RNA 系统进化分析表明，M. 属于一个非常深的分支 属于一个很深的分支，靠近古菌树的根部。然而，利用核糖体蛋白质的连接排列构建的树和基于基因含量的树进行的基因组比较表明，M. kandleri 与其他古甲烷菌一致。 M. kandleri 与其他古甲烷菌有相同的甲烷发生基因集，其操作体组织也部分与 和 和 热自养甲烷杆菌 .这些发现表明，古甲烷菌是单系的。坎德勒氏甲烷菌的一个显著特点是 Kandleri 的一个显著特点是缺乏参与信号传导和基因表达调控的蛋白质：另外、 此外，M. 通过横向转移获得的基因似乎少于其他古细菌。这些特征可能反映了这种生物的极端生境。
• Nutraceutical composition and method of use for treatment / prevention of cancer
  申请人：Mazzio Elizabeth

  公开号：US20070248693A1

  公开（公告）日：2007-10-25

  The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and/or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally one or more of frankincense, garcinia fruit, vitex , dragons blood, mace, sage and red sandalwood with at least c) one compound capable of maximizing oxidative mitochondrial function preferably riboflavin or vitamin B 2 derivatives, FAD, FMN, 5-amino-6-(5′-phosphoribitylamino)uracil, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B 1 , lipoic acid, biotin, vitamin B 6 , vitamin B 12 , folate, niacin, vitamin C and pantothenate and/or d) at least one lactic acid dehydrogenase inhibitor (preferably 2′,3,4′5,7-pentahydroxyflavone) and optionally f) an alkalizing agent ( aloe vera, chlorella , wheat grass, sodium or potassium bicarbonate, potassium) g) an antiproliferative herb ( speranskia or goldenseal) and h) a pharmaceutically acceptable carrier.
• US8802161B2
  申请人：——

  公开号：US8802161B2

  公开（公告）日：2014-08-12
• [EN] INHIBITION OF ANAEROBIC GLUCOSE METABOLISM AND CORRESPONDING NATURAL COMPOSITION AS A NON-TOXIC APPROACH TO CANCER TREATMENT<br/>[FR] INHIBITION DU METABOLISME DU GLUCOSE ANAEROBIE ET COMPOSITION NATURELLE CORRESPONDANTE COMME APPROCHE NON TOXIQUE DE TRAITEMENT DU CANCER
  申请人：MAZZIO ELIZABETH

  公开号：WO2006017494A2

  公开（公告）日：2006-02-16

  This invention discloses a method and formulation for treatment / prevention of human and animal cancers. The invention is designed to exploit the vulnerability of cancer with regards to its anaerobic requirement for non-oxidative phosphorylation of glucose to derive energy, being opposite to the host. The composition is comprised of one or more of (A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone, ubiquinones (5-45) (B) compound(s) capable of augmenting oxidative phosphorylation such as a riboflavin containing compound and/or ubiquinone (50) (C) 2',3,4'5,7-pentahydroxyflavone and/or a lactic acid dehydrogenase inhibitor and (D) compounds (s) that antagonize anapleurotic carboxylating pathways and gluconeogenesis from non-glucose carbon based substrates. This combination favors oxidative loss of carbon through decarboxylation reactions, suppresses carbon integration through gluconeogenesis and initiates collapse of ATP produced through glycolysis in tumor tissue, events which should be non-toxic or perhaps even beneficial to normal respiring host tissue. Pilot studies indicate the treatment to be potent without side effects.